STING1 and cancer: Although PARP7 and AHR expression levels as well as an intact STING signalling pathway will be needed to target PARP7-AHR-IFN signalling for cancer treatment, identifying which cancer cells or tumours will respond to such interventions will still require the identification of robust biomarkers.